Later Line Therapeutic Decisions in Metastatic HCC
Later Line Therapeutic Decisions in Metastatic HCC
February 2014
- A 63-year old male with HBV
- ECOG=0
- Child-Pugh A; platelet count 230,000 cells/mcL
- Bilirubin 1.0 mg/dL; Albumin 3.5 g/dL
- CT scan revealed liver lesions, 1 is 2-cm; 1 is 5-cm both in the right lobe
- No extrahepatic disease
- Biopsy confirmed HCC diagnosis
- AFP=5400 IU/ml
- Tumors were resected with RO margin
August 2016
- Imaging showed recurrence in the liver, metastatic disease in the lungs
- Therapy was initiated with sorafenib 400 mg BID
- Therapy was well-tolerated
April 2017
- Radiographic progression with multiple lung metastases
- ECOG=0
- Therapy with regorafenib initiated at 160 mg
- Starting dose was well-tolerated, patient experienced some fatigue
Recent Videos
Related Content
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024Article
A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
